ARID1A and cancer: Targeting the ATR/CHK1 axis triggers cancer cell-intrinsic innate immunity via the STING-mediated DNA-sensing pathway, thereby enhancing the therapeutic efficacy of radiotherapy (RT) and ICBs in ARID1A-deficient tumors.